{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:43:58Z","timestamp":1791211438480,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,7,30]],"date-time":"2012-07-30T00:00:00Z","timestamp":1343606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Carfilzomib is a next\u2010generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies, carfilzomib has shown efficacy in patients with relapsed and\/or refractory multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>) and has demonstrated a tolerable safety profile. In this phase 2, open\u2010label, multicentre clinical trial, 35 patients with relapsed and\/or refractory <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> following 1\u20133 prior therapies, including at least one bortezomib\u2010based regimen, received carfilzomib 20\u00a0mg\/m<jats:sup>2<\/jats:sup> in a twice\u2010weekly, consecutive\u2010day dosing schedule for \u226412\u00a0monthly cycles. The best overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>) was 17\u00b71% and the clinical benefit response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>\u00a0+\u00a0minimal response) was 31\u00b74%. The median duration of response was &gt;10\u00b76\u00a0months and the median time to progression was 4\u00b76\u00a0months. The most common adverse events were fatigue (62\u00b79%), nausea (60\u00b70%), and vomiting (42\u00b79%). No exacerbation of baseline peripheral neuropathy was observed. Single\u2010agent carfilzomib was generally well tolerated for up to 12 treatment cycles and showed activity in patients with relapsed and\/or refractory <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> who had received prior treatment with bortezomib. These data, combined with an acceptable toxicity profile, support the potential use of carfilzomib in patients with relapsed and\/or refractory <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> and warrant continued investigation of carfilzomib as single agent or in combination with other agents.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2012.09232.x","type":"journal-article","created":{"date-parts":[[2012,7,30]],"date-time":"2012-07-30T07:17:48Z","timestamp":1343632668000},"page":"739-748","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["An open\u2010label, single\u2010arm, phase 2 study of single\u2010agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib"],"prefix":"10.1111","volume":"158","author":[{"given":"Ravi","family":"Vij","sequence":"first","affiliation":[{"name":"Washington University School of Medicine St. Louis MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"Mayo Clinic Scottsdale AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McDonagh","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine Lexington KY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre University of Calgary Calgary AB Canada AB USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[{"name":"University of Alberta Cross Cancer Institute Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Kunkel","sequence":"additional","affiliation":[{"name":"Independent Consultant San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Wear","sequence":"additional","affiliation":[{"name":"Multiple Myeloma Research Consortium Norwalk CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin F.","family":"Wong","sequence":"additional","affiliation":[{"name":"Onyx Pharmaceuticals, Inc South San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,7,30]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Cancer Facts & Figures 2012","author":"ACS","year":"2012"},{"key":"e_1_2_8_3_1","first-page":"A411","article-title":"Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR\u2010171) in hematologic malignancies","volume":"110","author":"Alsina M.","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1950"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2011.04.008"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61029-X"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2010.08.008"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_8_13_1","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.00794.x"},{"key":"e_1_2_8_15_1","first-page":"6677","article-title":"Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells","volume":"51","author":"Kanayama H.","year":"1991","journal-title":"Cancer Research"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508"},{"key":"e_1_2_8_17_1","first-page":"A2765","article-title":"The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration","volume":"112","author":"Kirk C.J.","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9442-2"},{"key":"e_1_2_8_21_1","first-page":"A3031","article-title":"Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a phase 2 trial In patients with relapsed and refractory multiple myeloma (R\/R MM)","volume":"116","author":"Martin T.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012674"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.310"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07303.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0822"},{"key":"e_1_2_8_27_1","first-page":"374","article-title":"PX\u2010171\u2010007: a phase 1b study evaluating the safety and efficacy of a 30\u2010minute IV infusion of carfilzomib in patients with relapsed and\/or refractory (R\/R) multiple myeloma (MM) (Abstract 0898)","volume":"96","author":"Papadopoulos K.","year":"2011","journal-title":"Haematologica (Abstracts from the 16th Annual Congress of the EHA)"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223677"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/0003495-200868170-00008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2009.01.001"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_8_32_1","first-page":"A985","article-title":"The multiple myeloma research consortium results of PX\u2010171\u2010003\u2010A1, an open\u2010label, single\u2010arm, phase 2 (ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"Siegel D.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20121"},{"key":"e_1_2_8_34_1","first-page":"126","article-title":"A summary of safety and efficacy data achieved with long\u2010term carfilzomib (CFZ) treatment in patients with relapsed and\/or refractory multiple myeloma (R\/R MM)","volume":"96","author":"Siegel S.","year":"2011","journal-title":"Haematologica"},{"key":"e_1_2_8_35_1","article-title":"PX\u2010171\u2010003\u2010A1, an open\u2010label, single\u2010arm phase (Ph) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R\/R MM): long\u2010term follow\u2010up and subgroup analysis","volume":"29","author":"Siegel D.","year":"2011","journal-title":"Journal of Clinical Oncology (Meeting Abstracts)"},{"key":"e_1_2_8_36_1","article-title":"Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis","volume":"118","author":"Singhal S.","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_37_1","article-title":"Carfilzomib: high single agent response rate with minimal neuropathy even in high\u2010risk patients (Abstract)","volume":"116","author":"Vij R.","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414359"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2012.09232.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2012.09232.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T21:56:19Z","timestamp":1695506179000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2012.09232.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,30]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1365-2141.2012.09232.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09232.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,30]]},"assertion":[{"value":"2012-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}